Shimazaki A - Search Results

1

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.

Fuwa M, Ueda K, Akaishi T, Yamashita N, Kirihara T, Shimazaki A, Mano H, Kawazu K. Fuwa M, et al. Among authors: shimazaki a. PLoS One. 2016 Jul 6;11(7):e0158797. doi: 10.1371/journal.pone.0158797. eCollection 2016. PLoS One. 2016. PMID: 27383260 Free PMC article.

2

[Effects of ocular hypotensive agents on the circadian rhythm in intraocular pressure in rabbits as measured by telemetry].

Akaishi T, Shimazaki A, Matsugi T, Miyawaki N, Hara H, Kuwayama Y. Akaishi T, et al. Among authors: shimazaki a. Nippon Ganka Gakkai Zasshi. 2003 Sep;107(9):513-8. Nippon Ganka Gakkai Zasshi. 2003. PMID: 14531310 Japanese.

3

Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H. Takagi Y, et al. Among authors: shimazaki a. Exp Eye Res. 2004 Apr;78(4):767-76. doi: 10.1016/j.exer.2003.12.007. Exp Eye Res. 2004. PMID: 15037111

4

Effects of the new ethacrynic acid derivative SA9000 on intraocular pressure in cats and monkeys.

Shimazaki A, Ichikawa M, Rao PV, Kirihara T, Konomi K, Epstein DL, Hara H. Shimazaki A, et al. Biol Pharm Bull. 2004 Jul;27(7):1019-24. doi: 10.1248/bpb.27.1019. Biol Pharm Bull. 2004. PMID: 15256733 Free article.

5

Continuous monitoring of circadian variations in intraocular pressure by telemetry system throughout a 12-week treatment with timolol maleate in rabbits.

Akaishi T, Ishida N, Shimazaki A, Hara H, Kuwayama Y. Akaishi T, et al. Among authors: shimazaki a. J Ocul Pharmacol Ther. 2005 Dec;21(6):436-44. doi: 10.1089/jop.2005.21.436. J Ocul Pharmacol Ther. 2005. PMID: 16386085

6

Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys.

Shimazaki A, Kirihara T, Rao PV, Tajima H, Matsugi T, Epstein DL. Shimazaki A, et al. Biol Pharm Bull. 2007 Aug;30(8):1445-9. doi: 10.1248/bpb.30.1445. Biol Pharm Bull. 2007. PMID: 17666801 Free article.

7

Ocular hypotensive efficacy of Src-family tyrosine kinase inhibitors via different cellular actions from Rock inhibitors.

Kirihara T, Shimazaki A, Nakamura M, Miyawaki N. Kirihara T, et al. Among authors: shimazaki a. Exp Eye Res. 2014 Feb;119:97-105. doi: 10.1016/j.exer.2013.11.015. Epub 2013 Dec 7. Exp Eye Res. 2014. PMID: 24321889

8

Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.

Akaishi T, Shimazaki A, Tonouchi A, Ueda K, Miyawaki N, Kawazu K. Akaishi T, et al. Among authors: shimazaki a. J Ocul Pharmacol Ther. 2015 Nov;31(9):518-24. doi: 10.1089/jop.2015.0031. Epub 2015 Sep 1. J Ocul Pharmacol Ther. 2015. PMID: 26325164

9

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.

Esaki Y, Shimazaki A, Pellinen P. Esaki Y, et al. Among authors: shimazaki a. Open Ophthalmol J. 2016 May 31;10:146-53. doi: 10.2174/1874364101610010146. eCollection 2016. Open Ophthalmol J. 2016. PMID: 27347250 Free PMC article.

10

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.

Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, Shimazaki A, Matsugi T, Shams N, Zhang JZ. Kirihara T, et al. Among authors: shimazaki a. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):145-153. doi: 10.1167/iovs.17-22745. Invest Ophthalmol Vis Sci. 2018. PMID: 29332128

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters